Real-world treatment patterns and outcomes for patients with multiple myeloma in Denmark, Finland and Sweden: An analysis using linked Nordic registries
European Journal of Cancer · 2024-04 · 201 · 113921
DOI: 10.1016/j.ejca.2024.113921 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Cancer, 2024-04. Verfasst von Niels Abildgaard und 9 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Research Unit, Department of Hematology, Odense University Hospital, Odense, Denmark; Department of Clinical Research, University of South…. Hauptthemen laut MEDLINE: Multiple Myeloma, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Takeda Pharmaceutical Company, Takeda Pharmaceuticals International.
Abstract (Originalsprache)
AIM: The Health outcomes and Understanding of MyelomA multi-National Study (HUMANS) was a large-scale, retrospective study conducted across Denmark, Finland and Sweden using linked data from national registries. We describe the characteristics, treatment patterns and clinical outcomes for patients with newly diagnosed multiple myeloma (NDMM) over 2010-2018. METHODS: Patients with NDMM who received MM-specific, first-line treatments, were categorised by treatment (autologous stem cell transplantation [ASCT] or a combination chemotherapy regimen based on bortezomib, lenalidomide or melphalan-prednisolone-thalidomide). RESULTS: 11,023 patients received treatment over 2010-2018. Time between diagnosis and treatment was shortest in Denmark (0.9 months), then Sweden (2.9 months) and Finland (4.6 months). Around one third of patients underwent ASCT. Lenalidomide-based regimens were prescribed to 23-28% of patients in Denmark and Finland, versus 12% in Sweden. Patients receiving lenalidomide had the longest wait for treatment, from 3.2 months (Denmark) to 12.1 months (Sweden). Treatment persistence was highest among patients receiving melphalan-prednisolone-thalidomide (7-8 months) in Finland and Sweden and lowest among those receiving bortezomib (3.5 months) in Finland. Overall survival (OS) was longest among patients with ASCT (7-10 years). Among patients receiving chemotherapy, OS (from diagnosis/treatment initiation), varied between cohorts. In a sensitivity analysis excluding patients with smouldering MM, OS decreased for all; for patients receiving bortezomib or lenalidomide, OS from diagnosis was 40-49 and 27-54 months, respectively. CONCLUSIONS: This population-based study of patients with NDMM receiving first-line MM-specific treatment, provides real-world data on treatment patterns and outcomes to complement data from randomised clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hematology Research Unit, Department of Hematology, Odense University Hospital, Odense, Denmark; Department of Clinical Research, University of Southern Denmark, Odense, Denmark. Electronic address: niels.abildgaard@rsy…
- Comprehensive Cancer Center, Department of Hematology, University of Helsinki, and Helsinki University Hospital, Helsinki, Finland.
- Department of Hematology, St Olav's University Hospital, Trondheim, Norway.
- Research Unit OPEN, Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
- Takeda Pharmaceuticals International AG, Oslo, Norway.
- Takeda Pharmaceuticals International AG, Zurich, Switzerland.
Förderung
- Takeda Pharmaceutical Company
- Takeda Pharmaceuticals International
Zitieren
APA
Abildgaard, N., Anttila, P., Waage, A., Rubin, K. H., Ørstavik, S., Bent-Ennakhil, N., Gavini, F., Ma, Y., Freilich, J., & Hansson, M. (2024). Real-world treatment patterns and outcomes for patients with multiple myeloma in Denmark, Finland and Sweden: An analysis using linked Nordic registries. European Journal of Cancer, 201, 113921. https://doi.org/10.1016/j.ejca.2024.113921
Vancouver
Abildgaard N, Anttila P, Waage A, Rubin KH, Ørstavik S, Bent-Ennakhil N, et al. Real-world treatment patterns and outcomes for patients with multiple myeloma in Denmark, Finland and Sweden: An analysis using linked Nordic registries. European Journal of Cancer. 2024;201:113921. doi:10.1016/j.ejca.2024.113921
BibTeX
@article{Abildgaard2024,
author = {Abildgaard, Niels and Anttila, Pekka and Waage, Anders and Rubin, Katrine Hass and Ørstavik, Sigurd and Bent-Ennakhil, Nawal and Gavini, François and Ma, Yuanjun and Freilich, Jonatan and Hansson, Markus},
title = {Real-world treatment patterns and outcomes for patients with multiple myeloma in Denmark, Finland and Sweden: An analysis using linked Nordic registries},
journal = {European Journal of Cancer},
year = {2024},
volume = {201},
pages = {113921},
doi = {10.1016/j.ejca.2024.113921}
}
EUVIMED